Premier Alternatives

Precede Biosciences

Boston, MA · Founded 2021 · Privately Held (backing)

Developer of a liquid biopsy platform designed to provide resolution into disease-defining biology from a blood test. Precede Biosciences is based in Boston, MA and was founded in 2021. Its last reported valuation was $199 million in Oct 2025. It has raised $132 million.

Last reported valuation
$198.5M
Oct 2026
Priced at
—
Total raised
$132.0M
Last round
—

Precede Biosciences key facts

as of Oct 2026
  • Developer of a liquid biopsy platform designed to provide resolution into disease-defining biology from a blood test.
  • Precede Biosciences is valued at approximately $198.5M as of Oct 2026 (last reported valuation).
  • It has raised $132.0M; the latest was Later Stage VC ($83.5M) in Oct 2025.
  • Notable investors include Alexandria Venture Investments, Mirae Asset Capital, Qatar Investment Authority, Osage University Partners, Labcorp Venture Fund — 17 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$198.5M

Precede Biosciences's last reported valuation, Oct 2025. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Precede Biosciences with a free account
  • ·The complete investor list: 17 names
  • ·Watch Precede Biosciences: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Precede Biosciences funding rounds

No rounds on record

No funding rounds for Precede Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Precede Biosciences valuation

Precede Biosciences's last reported valuation was $199 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.

Precede Biosciences investors

17 investors are on record for Precede Biosciences, including Alexandria Venture Investments, Mirae Asset Capital, Qatar Investment Authority and Osage University Partners. By type, the record holds 6 venture capital firms, 1 asset manager and 1 private equity firm.

About Precede Biosciences

Developer of a liquid biopsy platform designed to provide resolution into disease-defining biology from a blood test. The company's platform profiles circulating chromatin and the DNA methylome from plasma, enabling researchers and clinicians to gain insight into the activation of individual genes and pathways in diseased tissues.

Sector
Healthcare
HQ
Boston, MA, United States
Founded
2021
Employees
48
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.